Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.
作者： Xiaojun Liu , Zhongxia Yang , Olivier Latchoumanin , Liang Qiao
关键词:
摘要: Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules transduce coinhibitory signals to immunocompetent and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) programmed death ligand-1 (PD-L1) two important great potential targeted cancer therapy. Several antibodies targeting PD-1 PD-L1 have been approved for clinical use. In this review, we focus on recent development of gastric (GC)
sagepub.com
sci-hub.se 参考文章(32)
Shohei Eto, Kozo Yoshikawa, Masaaki Nishi, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Takashi Iwata, Mitsuo Shimada, Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer. ,vol. 19, pp. 466- 471 ,(2016) , 10.1007/S10120-015-0519-7
Hiroaki Saito, Hirohiko Kuroda, Tomoyuki Matsunaga, Tomohiro Osaki, Masahide Ikeguchi, Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. Journal of Surgical Oncology. ,vol. 107, pp. 517- 522 ,(2013) , 10.1002/JSO.23281
Leisha A. Emens, Fadi S. Braiteh, Philippe Cassier, Jean-Pierre Delord, Joseph Paul Eder, Marcella Fasso, Yuanyuan Xiao, Yan Wang, Luciana Molinero, Daniel S. Chen, Ian Krop, Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) Cancer Research. ,vol. 75, pp. 2859- 2859 ,(2015) , 10.1158/1538-7445.AM2015-2859
Yunhui Zong, Fuliang Chu, Songbing He, Yu Jing, Sally A Hunsucker, Tina Yang, Ming Zhang, Sisi Ye, Yafen Li, Bin Liu, Jinle Tang, Huimin Meng, Gangli An, Lin Yang, Abstract 4094: Identification of co-inhibitory receptor expression on T cells from gastric cancer patients Cancer Research. ,vol. 74, pp. 4094- 4094 ,(2014) , 10.1158/1538-7445.AM2014-4094
Roy S. Herbst, Michael S. Gordon, Gregg Daniel Fine, Jeffrey Alan Sosman, Jean-Charles Soria, Omid Hamid, John D. Powderly, Howard A. Burris, Ahmad Mokatrin, Marcin Kowanetz, Maya Leabman, Maria Anderson, Daniel S. Chen, F. Stephen Hodi, A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Journal of Clinical Oncology. ,vol. 31, pp. 3000- 3000 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.3000
Changping Wu, Yibei Zhu, Jingting Jiang, Jiemin Zhao, Xue-Guang Zhang, Ning Xu, Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance Acta Histochemica. ,vol. 108, pp. 19- 24 ,(2006) , 10.1016/J.ACTHIS.2006.01.003
Bingbing Dai, Liang Xiao, Paul D Bryson, Jinxu Fang, Pin Wang, PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines. Molecular Therapy. ,vol. 20, pp. 1800- 1809 ,(2012) , 10.1038/MT.2012.98
Padmanee Sharma, James P. Allison, The future of immune checkpoint therapy Science. ,vol. 348, pp. 56- 61 ,(2015) , 10.1126/SCIENCE.AAA8172
A D'Incecco, M Andreozzi, V Ludovini, E Rossi, A Capodanno, L Landi, C Tibaldi, G Minuti, J Salvini, E Coppi, A Chella, G Fontanini, M E Filice, L Tornillo, R M Incensati, S Sani, L Crinò, L Terracciano, F Cappuzzo, PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British Journal of Cancer. ,vol. 112, pp. 95- 102 ,(2015) , 10.1038/BJC.2014.555
Yu Sunakawa, Heinz-Josef Lenz, Molecular Classification of Gastric Adenocarcinoma: Translating New Insights from The Cancer Genome Atlas Research Network Current Treatment Options in Oncology. ,vol. 16, pp. 17- 17 ,(2015) , 10.1007/S11864-015-0331-Y